MARKET

OKYO

OKYO

OKYO PHARMA LTD
NASDAQ
2.090
+0.100
+5.03%
After Hours: 2.175 +0.085 +4.07% 16:42 02/10 EST
OPEN
2.240
PREV CLOSE
1.990
HIGH
2.280
LOW
2.090
VOLUME
377.60K
TURNOVER
--
52 WEEK HIGH
3.349
52 WEEK LOW
1.010
MARKET CAP
80.37M
P/E (TTM)
-13.6691
1D
5D
1M
3M
1Y
5Y
1D
OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program
TipRanks · 10h ago
Okyo Pharma appoints Mantelli as Chief Medical Officer
TipRanks · 10h ago
Weekly Report: what happened at OKYO last week (0202-0206)?
Weekly Report · 1d ago
Weekly Report: what happened at OKYO last week (0126-0130)?
Weekly Report · 02/02 09:18
OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial
TipRanks · 01/30 22:52
OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting
TipRanks · 01/30 16:59
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
Barchart · 01/30 10:30
Analysts Are Bullish on Top Healthcare Stocks: Teva Pharmaceutical (TEVA), OKYO Pharma Limited Sponsored ADR (OKYO)
TipRanks · 01/29 11:40
More
About OKYO
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Webull offers OKYO Pharma Ltd stock information, including NASDAQ: OKYO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OKYO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OKYO stock methods without spending real money on the virtual paper trading platform.